Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature

Xiao-Jun Yang1,2, Fei-Yun Zheng1, Yun-Sheng Xu3 and Rong-Ying Ou1*

Abstract

Isolated superficial inguinal metastases without any extended intra-abdominal spread is a rare event in patients with ovarian carcinoma. Here we report an isolated superficial inguinal metastasis in a patient with primary ovarian cancer. A 54-year-old Chinese patient with primary ovarian cancer, had an isolated painless enlarged right groin swelling (3×2cm) as the only manifestation, preoperative pathology confirmed metastatic adenocarcinoma. Gynecologic examination, transvaginal ultrasonography of the abdominopelvic cavity revealed a 5-cm mixed, right adnexal mass. At exploratory laparotomy, there was little intra-abdominal tumor dissemination but 100 ml of faint yellow peritoneal fluid and a 5-cm right ovarian tumor with intact capsule. Staging operation was performed and postoperative pathology confirmed adenocarcinoma located within right ovarian, with no evidence of involvement of other sites. Then the patient received adjuvant chemotherapy for Stage IVB. Five years later, the patient is currently still alive without evidence of recurrent disease. This case indicate that ovarian carcinoma isn't a disease localized only within the intra-peritoneal cavity, isolated superficial inguinal lymph node metastasis might occur in rare cases via potential lymphatic and (or) hematogenous route under special conditions. We propose the need to investigate the possible mechanisms, risk factors, metastatic patterns, the biology and natural history of such patients in a large-scale and multicenter analysis. Furthermore, efforts should be made for earlier and differential diagnosis and finally prolong survival time for such patients.

Keywords: Ovarian cancer, Superficial inguinal lymph node, Lymphatic spread

Background

Ovarian carcinoma is the most frequent cause of death from gynecological malignancies in China [1]. The main reason of its high mortality is due to the lack of symptoms for early detecting. Over 70% of patients with ovarian carcinoma were diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage III or IV at their initial presentation [2]. The most frequent symptoms include abdominal pain, distension, early satiety, vaginal bleeding or a combination of these, and the most common sign present at initial visit is a pelvic mass [3]. Patients with ovarian cancer were reported to presented with distant metastatic deposits in the cervix, vagina, or vulva at their initial visit [4]. Lymph node metastasis occurred in about 14-70% of patients with ovarian carcinoma and distributed mainly in the pelvic and aortic region [5]. Nevertheless, it is uncommon to present superficial inguinal lymph node (SILN) metastasis in patients with early stage of ovarian carcinoma. Isolated SILN metastasis was a very rare event in patients with ovarian carcinoma [6]. Here we report a 54-year-old patient with complete clinicopathological data, who attacked by occult primary ovarian cancer limited within the right ovary, while initially presented with an asymptomatic isolated enlarged right SILN and confirmed to be a metastatic adenocarcinoma by preoperative pathological examination. Its potential implications in basic science research and clinical management are discussed.
Case description

In June 2008, a 54-year-old Chinese woman, postmenopausal for 8 years, presented to our hospital with complaints of an isolated painless enlarged mass at right groin. On gross inspection, a palpable painless enlarged subcutaneous swelling (3 × 2 cm) were observed within the right groin. The contralateral inguinal nodes and the scalene nodes were clinically negative. Gynecologic examination showed a 5 cm fixed mass within the right adnexa. Transvaginal ultrasonography (TVUSG) showed a 5 × 4 × 5 cm mixed lump within the right adnexa, has relatively rich blood supply signals on the circumference and inside tumor, with papillary vegetation and irregular septa, together with a small amount of pelvic fluid (Figure 1). Results of endometrial and cervical biopsies, thyroid sonography, gastroduodenoscopy, colonoscopy, were all negative. Serum tumor markers including CA125 were all within normal range. Systematic infectious disease that can cause enlarged inguinal lymph node were analyzed, including hepatitis A, hepatitis B, hepatitis C, syphilis, HIV, HSV, and the results were all negative. No ulcers were presented in the lower genital tract. Patient was also screen for potential presence of Trichomonas vaginalis, genital Chlamydia trachomatis, and Neisseria gonorrhoeae, and results were all negative. Five days later, the patient received fine needle aspiration for the right groin swelling and preoperative pathological examination confirmed a metastatic adenocarcinoma (Figure 2).

Eleven days later, exploratory laparotomy were performed, there was little intra-abdominal tumor dissemination but 100 ml of faint yellow peritoneal fluid and a 5-cm right ovarian tumor with intact capsule, the rest of abdominopelvic cavity remained macroscopically negative. During the surgery, frozen sections for right adnexal mass revealed a low-grade differentiated serous ovarian papilliferous cystadenocarcinoma. According to procedures of staging operation for ovarian carcinoma [2], total abdominal hysterectomy, bilateral salpingo-ovariectomy, complete removal of the omentum, appendectomy, random biopsies of the peritoneum, systematic pelvic and paraaortic lymphadenectomy were performed,
completed with excision of the enlarged node in the right groin.

Postoperative pathologic diagnosis showed a poorly differentiated serous papilliferous cystadenocarcinoma of the right ovary (Figure 3), and right inguinal lymph node metastasis (Figure 4), which consistent with preoperative fine needle aspiration, immunohistochemical staining showed positive cytoplasmic CA125 expression both in ovarian cancer tissues (Figure 5) and in metastatic SILN (Figure 6), cytology of the pelvic fluid showed poor differentiated adenocarcinoma cells (FIGO G3). The rest of pathological diagnosis showed no evidence of disseminated intraperitoneal and retroperitoneal metastatic disease, all pelvic and paraaortic lymph nodes were negative (Figure 7). The patient was diagnosed to be FIGO Stage IVB [7] and then referred to postoperative adjuvant chemotherapy with paclitaxel (175 mg/m²) and carboplatin (AUC-5) at 28-day intervals for six cycles. Chemotherapy was completed in January 2009. Presently, five years after the primary diagnosis, this patient is still alive with no evidence of recurrent disease.

Discussion
Incidence of inguinal lymph node metastasis
Lymph node metastases can be well recognized in ovarian cancer with sampling of retroperitoneal lymph nodes as an integral part of the staging operation [8]. FIGO introduced inguinal lymph node involvement into the definition of stage IVB in ovarian carcinoma since 2013 [7], while patients exhibited metastatic retroperitoneal lymph nodes are classified as stage IIIC even when the primary tumor is limited to the pelvis [9]. The most common way of spreading in ovarian carcinoma is lymphatic metastasis and transcoelomic spread to adjacent viscera, with distant metastasis often concurring with extensive intra-abdominal dissemination [10]. Nevertheless, isolated SILN involvement in patients without any extended intraabdominal spread is a rare event [6,11,12].

The incidence of inguinal lymph node metastasis in ovarian carcinoma was approximately 3-5% as reported in literatures [6,11,13,14], while these studies can't provide enough clinical informations and pathological features. A little bit more detailed descriptions include following cases. A patient presenting with an enlarged inguinal lymph node, was finally diagnosed to be endometrioid carcinoma of the ovary [15]; a patient presented with metastatic inguinal lymphadenopathy was confirmed with poorly differentiated ovarian malignancy until 33 months later [16]; an eighteen-year old female patient complained with enlarged inguinal lymph nodes
and secondary lymphedema of both legs, showed ovarian
tumors (approximately 6 cm diameter) detected by com-
puted tomography, and was finally proved to be stromal
infiltration of signet-ring cell carcinoma in both ovaries
[17]; a 48-year-old patient presented with 6-month his-
tory of inguinal swelling, was confirmed with a serous
papillary ovarian carcinoma, thus indicated that inguinal
lymphadenopathy can be initial symptom epithelial ovar-
ian carcinoma [18]. Nevertheless, these studies were also
inconclusive, since they neglected to give any further de-
tailed information on pathological examination of the
pelvic and paraaortic lymph nodes, and whether inguinal
lymph node metastasis occurred in isolation or con-
curred with other sites of neoplasm metastasis.

To the best of our knowledge, the following three re-
cords provided full clinicopathological features in this
regards. Scholz et al. [19] firstly reported a patient with
undifferentiated serous adenocarcinoma of both ovaries
(10 × 5.5 cm), and involvement of fimbria of the right
fallopian tube, and positive peritoneal washing, initially
displayed an isolated left inguinal node metastasis, with-
out other nodal groups involvement. Then Manci et al.
[20] reported that, a patient complained with bilateral
inguinal lymphadenopathy, showed an increased uptake
of fluorodeoxyglucose in the inguinal and both adnexal
areas as detected by [(18)F] fluorodeoxyglucose (FDG)
positron emission tomography (PET), then post-
operational pathological diagnosis confirmed low-grade
differentiation serous papilliferous adenocarcinoma of
both ovaries (size not known), and metastatic bilateral
inguinal lymph nodes, without any intraperitoneal or
lymphatic spread. Afterwards, Ang et al. [21] reported a
patient with left ovarian adenocarcinoma (9.0 × 6.4 cm)
presented with isolated metastasis to the right inguinal
lymph node, there were no other sites of involvement.
Thus, the case we reported was one of the few cases
which have complete clinicopathological informations in
existing literatures. However, different from Scholz’s and
Ang’s case, in which large (10 × 5.5 cm) and (9.0 × 6.4
cm) tumor burden were found, our case demonstrated
relatively small tumor burden (5 cm in largest diameter),
disease was localized only within the right ovary, initially
presented with right SILN metastasis, without any evi-
dence of extensive intra-abdominal dissemination, and
retroperitoneal pelvic or paraaortic lymph nodes metas-
tasis. Therefore, this is the fourth case of ovarian carcin-
oma which presented with isolated SILN metastasis
reported in existing literatures.

**Diagnosis and prognosis**

Ovarian carcinoma usually presents with advanced stage
at their initial visit (FIGO Stage III and IV), with signs
and symptoms related to the diffused intraperitoneal dis-
b ease [2]. However, the presence of asymptomatic isolated
SILN at the time of first visit frequently creates a diag-
nostic dilemma. This situation is unique not only in the
manner of disease presentation, but also in the time lag
from first seeking advice to evidence of intra-abdominal
malignancy [16].

In general, the common condition which might pre-
sented with palpable SILN enlargement include meta-
static disease or secondary inflammation [22]. Pathology
of tumors commonly metastasising to the inguinal
lymph nodes include breast cancer [23]; tumours arising
from the vulva and lower third of the vagina [24]; pelvic
malignancies [25]; malignant tumours of the skin, most
commonly primary malignant melanoma or squamous
cell carcinoma arising on the legs and trunk [14,24];
squamous cell carcinoma of the anal canal is also a com-
mon gastrointestinal tumour to metastasise to the in-
guinal lymph nodes [24]. Systematic infectious disease
such as syphilis, HIV, HSV, and local infection such as ulcers in the lower genital tract, Neisseria gonorrhoeae, can also cause enlarged inguinal lymph node. Therefore, pre-operative diagnosis of inguinal lymph node enlargement always cause diagnostic dilemma and might involve general practitioners, oncologists, dermatologists, and specialist nurses. However, antibiotics treatment for 4 to 6 week is usually prescribed, followed by re-evaluation of the lymphadenopathy [24]. Previous literature showed that, for patients with isolated inguinal metastasis of unknown origin, laparoscopic surgery provided a minimally invasive diagnostic approach of the abdominal and pelvic cavity, although there controversy that a small tumor within the ovary might be missed [22]. Imaging examination such as TVUSG maybe helpful in detecting the earlier malignancy in ovary. PET might have an appropriate role in the diagnosis of occult ovarian neoplasm, even in the absence of a CA125 elevation [20]. The combination of FDG-PET/CT was successfully used to identify ovarian cancer recurrence in an inguinal hernia sac [26]. Moreover, serum levels of tumor markers such as CA125 can also assist to determine the primary disease when the clinical presentation is atypical or confusing. However, in our case, we proposed that, the management of a patient presenting with inguinal enlargement of unknown origin should include at least a detailed case history collection, complete gynecological examination and some useful auxiliary diagnostic measures for any ovarian neoplasms. Sometimes, even if no evident clinical signs and symptoms of a tumor in the lower genital tract, isolated enlarged SILN should also be paid enough attention for possible existence of an occult malignant ovarian tumor. In other words, ovarian cancer should be part of the differential diagnosis in women with inguinal lymphadenopathy even without any clinical evidence of intra-abdominal disease. Furthermore, surgical excision or lymph node biopsy can be a indication for inguinal lymphadenectomy, can provide better diagnostic and prognostic information.

The role of lymph node metastasis on survival in ovarian cancer has been a matter of debate over the years [27]. Generally, lymph node metastasis is recognized as a parameter of unfavorable prognosis. The prognosis of distant metastasis in ovarian carcinoma is poor and the median survival was only about 12 months [28]. While the opposite view suggested that, patients with ovarian carcinoma which upstaged to stage III based solely on systematic lymphadenectomy, have similar survival to stage I/II patients and superior survival to other stage III patients [29]. In fact, survival difference between node-positive-only stage IIIIC and intra-abdominal stage IIIIC simply reflect the prognostic impact of small versus large tumor size [30]. "Node-positive-only" stage IIIIC have a more favorable outcome than intra-abdominal stage IIIIC and IIB in patients with epithelial ovarian cancer [31,32].

The impact of SILN metastasis on the prognosis in ovarian cancer is also in controversy. Some authors suggested that patients with inguinal lymph node metastasis as their first symptoms were associated with poor prognosis, and can only survive for about three years [16,18]. While others argued that, in patients with recurrent epithelial carcinoma, who presented as isolated lymph node metastases (including inguinal nodal involvement), complete optimal secondary cytoreductive surgery was achievable in the majority of cases and were associated with relatively favorable long-term survival outcome [33,34]. Similar study also indicated that, for those suffered with serous carcinoma of the ovary, fallopian tube, or peritoneum, distant lymph node metastasis was an uncommon event (including inguinal nodal involvement), however, this rare presentation does not adversely affect survival, patients with minimal intra-peritoneal disease and extra-abdominal lymph node metastases survive longer than those with bulky peritoneal disease [35]. According to the new stage system, inguinal lymph node metastasis was classified into FIGO Stage IVB ovarian cancer [7]. While in the previous edition of stage system, it was confusion about this, and inguinal lymph node metastasis was usually put into Stage IIIc [9]. Therefore, we supposed that, such stage difference might cause inconsistency in data analysis on prognosis regarding inguinal lymph node metastasis.

The case reported here, was confirmed to be Stage IVB ovarian cancer, and survive for five years after six rounds of carboplatin plus paclitaxel systematic chemotherapy, with no evidence of recurrence. We consider it that such patients presented only with distant lymphatic metastasis, were in relatively better conditions and specific immune status, thus have better prognosis after comprehensive treatment, as compared with bulky peritoneal disease. However, with the issue of new stage system in the year of 2013 [7], large-scale and multicenter analysis should be done to investigate clinical outcome in patients with ovarian cancer confined to the ovary but upstaged to stage IVB due to metastatic SILN, and provide more insight about potential differences in biological and clinical behavior of inguinal lymph node versus intra-peritoneal metastasis. Furthermore, there is no existing guideline on definitive management of patients with ovarian cancers metastasizing to isolated SILN [22], efforts should be made to improve early diagnosis and finally prolong the survival of such patients. We suggested that, such patients should be entered into clinical trials of different treatment modalities in order to develop optimal clinical guideline.

Routes and mechanisms of lymphatic metastasis

Generally, ovarian cancer has three routes for lymphatic metastasis [36,37]. Firstly, lymphatic vessels mainly
accompany the ovarian vessels within the infundibulo-pelvic ligament towards the paraaortic and paracaval lymph nodes. Thus, nodes running parallel to lymphatic vessels are at highest risk of involvement. Once the pelvic and paraaortic lymph nodes have been involved, lymphatic channels within the diaphragm and retroperitoneum will facilitate dissemination above the diaphragm. Less commonly, the second route follows the subovarian plexus in the bilateral broad ligament towards the obturator and pelvic iliac lymph nodes. The third potential route follows the bilateral round ligament of the uterus to the external iliac and deep inguinal lymph nodes. We suggested that, in the absence of paraaortic or pelvic lymphadenopathy which mainly depend on the first and the second route as above mentioned, the isolated SILN metastasis might attribute to the third potential channel. Our case just provided support to lymphatic dissemination via this potential channel, through which ovarian cancer metastasize from the round ligament to deep inguinal lymph node and finally drained towards the SILN. However, the existence of such a potential pathway has not been confirmed yet. Moreover, hematogenous dissemination is also another possible pathway for this special metastatic pattern, and was reported to occur in approximately 2% to 3% of patients with primary ovarian carcinoma [10]. Theoretically, hematogenous route may account for dissemination to any distant sites in ovarian cancer. Such as, early extra-abdominal metastases [38], central nervous system metastases [39], axillary lymph nodes [40], and breast metastases [41,42], all support the model of spreading through hematogenous route. Therefore, in summary, we proposed that the event of isolated SILN metastasis in ovarian cancer potentially involved two channels: via deep inguinal lymphatic routes through round ligament and/or hematogenous route.

In addition to study the routes of isolated SILN metastasis in ovarian cancer, we should also explore its underlying mechanisms. Current study revealed that advanced tumor stage, low-grade cell differentiation were risk factors for the development of distant metastasis [28]. For instance, in our case with G3, low-grade cell differentiation might contribute to one of important risk factors for isolated SILN metastasis. In addition, mutation of p53 tumor suppressor gene was more likely to be associated with distant lymph node metastases in ovarian cancer; indicated that gene mutation and vascularization might also contribute to distant metastasis in ovarian cancer [43]. Moreover, we speculated that, this special metastatic pattern is probably the result of tumor biology and host-tumor immunostatus. The special host immune state within a specific time window perhaps plays a key role, might kill some primary cancer cells but neglect distant isolated lymph node metastasis. Nevertheless, there may be a number of other unknown factors beyond our present knowledge, such as unexplained hormones contributions. Existing literatures have put more emphasis on pelvic and paraaortic lymph nodes metastasis in ovarian cancer [36]. However, few studies had focused on the isolated SILN metastasis, the exact molecular mechanisms and/or risk factors of this special clinic metastatic pattern in ovarian cancer still deserve further investigation.

Conclusions
Ovarian carcinoma isn’t a disease localized only within the intraperitoneal cavity, isolated SILN metastasis can occur and present as an initial symptom in rare case with relative initial tumor origin stage, via potential lymphatic and (or) hematogenous route under special mechanisms which might include roles of immunological, pathological and hormonal factors. On the other hand, it should be kept in mind that inguinal masses might be the metastatic lesions of ovarian cancer. A proper preoperative evaluation including gynecological exam, cervicovaginal smear, CA 125 level and TVUSG must be performed in such cases.

Consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
FIGO: International Federation of Gynecology and Obstetrics; FDG: Fluorodeoxyglucose; PET: Positron emission tomography; SILN: Superficial inguinal lymph node; TVUSG: Transvaginal ultrasonography.

Competing interests
The authors declared that they have no competing interests, have no commercial, proprietary, or financial interest in the products or companies described in this article. X-J.Y. has nothing to disclose. F-Y.Z. has nothing to disclose. Y-S.X. has nothing to disclose. R-Y.O. has nothing to disclose.

Authors’ contributions
X-J.Y. and R-Y.O. have contributed significantly in drafting the manuscript, literature review and revising it critically. F-Y.Z. provided the clinical data, Y-S.X. and R-Y.O. also involved in immunohistochemical staining of CA125, pathological diagnosis. All the authors had read and approved the final manuscript.

Acknowledgements
This work was supported in part by a grant from Zhejiang Provincial Natural Science Foundation of China (Grant No. LYG12H04004), and National Natural Science Foundation of China (Grant No. 81373075, 81371748). There were no competing interests.

Funding
This project was funded in part by Zhejiang Provincial National Natural Science Foundation of China (Grant LY12H04004) and National Science Foundation of China (Grant No. 81373075, 81371748).

Author details
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow
University, Suzzhou 215006, China. Department of dermatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Received: 30 September 2013 Accepted: 5 February 2014
Published: 10 February 2014

References
1. Li J, Yang W, Wu X: Prognostic factors and role of salvage surgery in chemoresistant ovarian germ cell malignancies: a study in Chinese patients. Gynecol Oncol 2007, 105:S69–755.
2. Hand R, Frengten A, Chmiel JS, Recant W, Berk R, Sylvester J, Sener S: Staging procedures, clinical management, and survival outcome for ovarian carcinoma. JAMA 1993, 269:119–122.
3. Smith EM, Anderson B: The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer 1985, 56:277–2732.
4. Guidozi F, Sonnendecker EW, Wright C: Ovarian cancer with metastatic deposits in the cervix, vagina, or vulva preceding primary cytoreductive surgery. Gynecol Oncol 1993, 49:225–235.
5. Panico PB, Angioli R: Role of lymphadenectomy in ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002, 16:59–551.
6. Rose PG, Piver MS, Tsukada Y, Lau TS: Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989, 64:1508–1512.
7. Prat J: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 2014, 124:1–5.
8. Hermannek P, Scheibe O, Speier B, Wagner G: TNM classification of malignant tumors: the new 1987 edition. Rontgen-Blatter 1987, 40:200.
9. The Oncology Committee of the International Federation of Gynecologists and Obstetricians: FIGO news. Changes to the 1985 FIGO report on the result of treatment in gynecological cancer. Int J Gynecol Obstet 1987, 25:87–88.
10. Berek JS, Hacker NF: Practical Gynecologic Oncology. 3rd edition. Philadelphia: Lippincott Williams and Wilkins; 2000.
11. Dvoretsky PM, Richards KA, Angel C, Rabinowitz L, Stoler MH, Beecham JB: Patterns of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 1988, 19:57–63.
12. Abrams HL, Sprio R, Goldstein N: Metastasis in carcinoma; analysis of 1000 autopsied cases. Cancer 1950, 3:34–85.
13. Musueinci R, Bariti A, Bolis G, Candiani GB, De Palo G, Di Re F, Lucia L, Lattuada A, Mangioni C, Mattioli G, Natale N: Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive cases. Cancer 1977, 40:1444–1449.
14. Zaren HA, Copeland EM 3rd: Inguinal node metastases. Cancer 1978, 41:919–923.
15. McGonigle KF, Dubbins MR: Endometrioid carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominopelvic carcinoma. Gynecol Oncol 1992, 45:225–228.
16. Kehoe S, Luksley D, Rollason T: Ovarian carcinoma presenting with Inguinal Metastatic Lymphadenopathy 33 Months prior to intraabdominal disease. Gynecol Oncol 1993, 50:218–30.
17. Dose J, Jamieck F, Sernekwisth R, Avril N, Nathnath W, Kolben M, Graeff H: Signet-ring cell carcinoma of both ovaries of unknown origin in an 18-year-old patient - attempt of an immunotherapy with the Monoclonal-Antibody-B72-3, Tumordiagnostik u Therapie 1995, 16:153–157.
18. Chen CA, Huang SH, How SW, Hsieh CY: Systemic Lymphadenopathy as the primary symptom of serous surface papillary carcinoma of the ovary. Gynecol Oncol 1995, 58:251–254.
19. Scholz HS, Lax S, Tamussino KF, Peruta E: Inguinal lymph node metastasis as the only manifestation of lymphatic spread in ovarian cancer: a case report. Gynecol Oncol 1999, 75:17–518.
20. Manci N, Bellati F, Graziano M, Pernice M, Muzii L, Angioli R, Panici PB: Ovarian cancer, diagnosed with PET, with bilateral inguinal lymphadenopathy as primary presenting sign. Gynecol Oncol 2006, 100:621–622.
21. Ang D, Nip KY, Tan HK, Chung AYF, Yew BS, Lee WK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singap 2007, 36:427–430.
22. Guarischi A, Keane TJ, Elhakim T: Metastatic inguinal nodes from an unknown primary neoplasm – a review of 56 cases. Cancer 1987, 59:572–577.
23. Baba M, Tatsuta M, Miya A, Ishida H, Masutani S, Kawasaki T, Satomi T, Hanai J, Kimura F: A case of breast cancer diagnosed by inguinal lymph node metastasis. Breast Cancer 2000, 7:173–175.
24. Swan MC, Fumiss D, Cassell OC: Surgical management of metastatic inguinal lymphadenopathy. BMJ: British Medical Journal 2004, 329:1272–1276.
25. Digel CA, Lastner GM, Zinreich ES: The use of transmission block in the radiation therapy portal treatment of the inguinal nodes in late stage pelvic malignancies. Radiat Technol 1987, 58:227–231.
26. Diaz-Montes TP, Jacene WA, Wahl RL, Bristow RE: Combined FDG-potposit emission tomography and computed tomography for the detection of ovarian carcinoma recurrence in an inguinal hernia sac. Gynecol Oncol 2005, 98:510–512.
27. Di Re F, Boccioghi G: Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium. Int J Gynecol Cancer 2000, 10:435–442.
28. Cormio G, Rossi C, Cazzolla A, Resta L, Lavorero G, Greco P, Selvaggi L: Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003, 13:525–547.
29. Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakaqwara S, Yamada M, Matsumoto K, Taketani Y: Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage III patients and superior survival to other stage III patients. Cancer 1998, 83:1555–1560.
30. Herzog TJ: Assessing the adequacy of surgical staging for ovarian cancer. Gynecol Oncol 2006, 103:781–782.
31. Clabby WA, Aletti GD, Wilson TO, Podratz KC: Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 2006, 103:397–401.
32. Ferrandina G, Sambia G, Legge F, Perrillo M, Sabatini V: Ovarian cancer patients with “node-positive-only” stage IIB disease have a more favorable outcome than stage IIIA/B. Gynecol Oncol 2007, 107:154–156.
33. Santillan A, Karam AK, Li AJ, Giuntoli R, Gardner GJ, Cass I, Karlan BY, Bristow RE: Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 2007, 104:686–690.
34. Blanchard P, Plantade A, Pages C, Alphan P, Louvet C, Tourmijard C, de Gramont A: Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol 2007, 104:41–45.
35. Euscher ED, Silva EG, Deavers MT, Elshaev E, Gershenson DM, Malpica A: Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol 2004, 28:1217–1223.
36. Burghardi E, Girardi F, Lahuosen M, Tamussino K, Stettner H: Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991, 40:103–106.
37. Eichner E, Bove ER: In vivo studies on the lymphatic drainage of the human ovary. Obstet Gynecol 1954, 3:287–297.
38. Pickel H, Lahuosen M, Girardi F, Tamussino K, Stettner H: Intraperitoneal and retroperitoneal spread of ovarian cancer: In Ovarian Cancer: Biological and Therapeutic Challenges. Edited by Sharp F, Mason WP, Leake RE. London: Chapman & Hall Medical; 1989:171–178.
39. Kumar L, Barge S, Mahapatra AK, Thukral S, Rath GK, Kumar S, Mishra R, Dawar R, Singh R: Central nervous system metastases from primary epithelial ovarian cancer. Cancer Control 2003, 10:244–253.
40. Hockstein S, Keel P, Lurian JR, Fishman DA: Ovarian carcinoma initially presenting as metastatic axillary lymphadenopathy. Gynecol Oncol 1997, 64:537–541.
41. Duda RB, August CZ, Schink JC: Ovarian carcinoma metastatic to the breast and axillary node. Surgery 1991, 110:552–556.
42. Loredo D, Powell JL, Reed WP, Rosenbaum JM: Ovarian carcinoma metastatic to breast: a case report and review of the literature. Gynecol Oncol 1990, 37:432–436.
43. Sood AK, Sorosky JL, Dolan M, Anderson B, Buller RE: Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 1999, 5:2485–2490.

Cite this article as: Yang et al. Ovarian cancer initially presenting with isolated ipsilateral superficial inguinal lymph node metastasis: a case study and review of the literature. Journal of Ovarian Research 2014 7:20.